Celcuity Inc CELC

$72.10 -3.03 (-4.03%)

Valuation

Market cap
3,676,260,000
Revenue TTM
$0
Net income TTM
$-177,040,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,421,100
Avg volume
941,366
Day's range
$70.68 – $75.44
Shares out
48,932,000
Stochastic %K
8%
Beta
0.11
Analysts
Strong Sell
Price target
$160.25

Price

Company profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients wi...

Show more

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Industry
Biotechnology
Sector
Healthcare
Phone
(763) 392-0123
Website
https://www.celcuity.com
Address
2800 Campus Drive, Suite 140, Minneapolis, United States

Latest news

Stocktwits

heffer Oct 3, 10:49 AM
$CELC I think this gets bought soon. 110% institutional . An increase from the dip. It would easily fit a BP oncology profile.
0 replies
Uncle_Baby_Billy Oct 3, 4:00 AM
$CELC Just hold your nose and buy. You’ll thank me later
0 replies
Florestan Oct 3, 2:12 AM
$CELC the year's a write off. Nothing will happen until sales number comes. Until then.
0 replies
CharlieeMungerTWITS Oct 3, 12:13 AM
$CELC If CELC had collapsed from $100 to $72 while XBI was ripping higher and LABD was collapsing, I’d be considerably more concerned. That would suggest CELC-specific selling. But that’s not what’s up… Instead, you’ve had a pretty nasty risk-off environment for biotech and smaller-cap equities generally. The broader market has also become unusually narrow. LABD up like 30%. The WSJ reports that since September nearly 80% of S&P 500 stocks have declined, while AI-related mega-caps have masked much of the weakness in the headline indexes. Small caps have been particularly weak. $ETON $CORT
0 replies
Stocks2Retire Oct 2, 8:11 PM
$CELC this price action has become very common in biotechs however big or small it is.. run up on approval anticipation ..then sell off .. then go thru a phase of early commercialization where the promise of the drug … conversion into adoption and revenue trend is closely watched..only some news on commercialization status with some numbers.. will help.
1 replies
ImFullyTorqued Oct 2, 7:52 PM
$CELC me buying at 140
0 replies
HappyStockholder Oct 2, 7:21 PM
$CELC I’m just going to sit back and shut up. I couldn’t have been more wrong about this stock’s performance. I’m speechless. Still holding and hopeful.
1 replies
Jmk111 Oct 2, 7:03 PM
$CELC shake the trees!!! Never amazes me how weak people are. Holding & adding since 2/1/2018 Investment of a lifetime
1 replies